ness, are now being raised as arguments against randomised trials of diagnostic techniques” (8). This still applies (at least partly) in 2012. However, as with RCTs in drug interventions, we expect that the value of RCTs in diagnostic imaging in general and in PET in particular will be increasingly acknowledged. In the meantime we are looking forward to an objective and “evidence-based” discussion on this issue.

REFERENCES


Erratum

There were some errors in the Acknowledgments section of “18F-FPRGD2 and 18F-FDG PET of Response to Abraxane Therapy,” by Sun et al. (J Nucl Med. 2011;52:140–146). The corrected Acknowledgments appear below. The authors regret the error.

We thank Dr. Henry S. Eden for proofreading the manuscript. This project was supported, in part, by the Department of Defense (DOD) Breast Cancer Research Program (BCRP) (W81XWH-04-01-0697); the Intramural Research Program of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH); and the Radiology and Imaging Sciences Department, NIH Clinical Center.
Erratum


This article and updated information are available at:
http://jnm.snmjournals.org/content/53/11/1824

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml